nach oben

Erschienen in:

01.10.2014 | Review Article

Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis

verfasst von: Francesco Bertagna, Mattia Bertoli, Giovanni Bosio, Giorgio Biasiotto, Ramin Sadeghi, Raffaele Giubbini, Giorgio Treglia

Erschienen in: Hepatology International | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The role of fluorine-18-fluorodeoxygluose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) in hepatocellular carcinoma (HCC) has not been firmly established yet and its sensitivity has been reported to be in the range of 40–60 %. Because of this relatively low sensitivity alternative tracers have been proposed. The aim of our review is to analyse the literature data on the diagnostic role of ¹⁸F/¹¹C-choline PET/CT in the evaluation of HCC. A comprehensive computer literature search of PubMed/MEDLINE, Embase and Scopus databases was conducted to find relevant published articles about the role of whole-body ¹⁸F-choline or ¹¹C-choline PET or PET/CT in patients with HCC. Furthermore, a meta-analysis about the detection rate of this method in HCC was performed. Six articles were included in this systematic review and discussed. The meta-analysis of five out of six articles showed a DR of 84 % (95 % CI 79–89 %). The DR increased when poorly differentiated HCC was excluded from the analysis. Radiolabelled choline PET or PET/CT could be a valuable tool in detecting HCC and it is better than ¹⁸F-FDG PET/CT, especially in well to moderately differentiated lesions; on the other hand, poorly differentiated and higher-stage HCC could be better evaluated with ¹⁸F-FDG and dual tracer imaging should be considered and could be potentially useful to increase accuracy.

Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32:225–237PubMedCrossRef

Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74–108PubMedCrossRef

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–156PubMedCrossRef

Hussain SM, Semelka RC, Mitchell DG. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am. 2002;10:31–52PubMedCrossRef

Lee KHY, O’Malley ME, Kachura JR, Haider M, Hanbidge A. Hepatocellular carcinoma: imaging and imaging guided intervention. Am J Roentgenol. 2003;180:1015–1022CrossRef

Wudel LJ Jr, Delbeke D, Morris D, Rice M, Washington MK, Shyr Y, et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg. 2003;69:117–124PubMed

Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol. 2008;33:1047–1054PubMed

Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al. Evaluation of liver tumors using fluorine-18-fluorodexyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992;33:333–339PubMed

Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510–515PubMedCrossRef

10.

Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314–3319PubMedCrossRef

11.

Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med. 2007;48:902–909PubMedCrossRef

12.

Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213–221PubMed

13.

Hwang KH, Choi DJ, Lee SY, Lee MK, Choe W. Evaluation of patients with hepatocellular carcinomas using [11C]acetate and [18F]FDG PET/CT: a preliminary study. Appl Radiat Isot. 2009;67:1195–1198PubMedCrossRef

14.

Cheung TT, Ho CL, Lo CM, Chen S, Chan SC, Chok KS, et al. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon’s perspective. J Nucl Med. 2013;54:192–200PubMedCrossRef

15.

Barwick T, Zerizer I, Al-Nahhas A. Clinical dilemmas in primary liver cancer. Value of PET scanning. 2011. doi:10.1002/9781119962205.ch17. Print ISBN: 9780470657973. Online ISBN: 9781119962205

16.

Corn D, Jesberger J, Kolthammer J, Flask C, Lee Z. Dual-modality imaging of hepatocellular carcinoma. Cancer Res. 2011;71(Suppl 1). doi:10.1158/1538-7445.AM2011-5297.

17.

Goh V, Sarker D, Osmany S, Cook GJ. Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:1070–1079PubMedCrossRef

18.

He TT, Tian JH. Application of positron emission tomography molecular probes in hepatocellular carcinoma biological imaging. Chin Med Sci J. 2011;26(2):113–118PubMedCrossRef

19.

Jadvar H. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers. Semin Nucl Med. 2012;42:247–254PubMed

20.

Kolthammer JA, Corn DJ, Wu C, Tenley NP, Wang Y, Lee Z. Same-session comparison of fluorocholine and choline for PET imaging of hepatocellular carcinoma. Mol Imaging Biol. 2010;12(Suppl 2):S1200

21.

Kumar R, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 2. Expert Rev Anticancer Ther. 2006;6(4):625–640PubMedCrossRef

22.

Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007;37:420–428PubMedCrossRef

23.

Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging. 2010;37:2188–2193PubMedCrossRef

24.

Skoura E, Datseris IE. The use of 18F-fluorothymidine and 18F-fluorocholine in imaging with positron emission tomography. Hell J Nucl Med. 2010;13:88–90PubMed

25.

Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med. 2012;26:451–461PubMedCrossRef

26.

Vutrapongwatana U, Juiklom W, Wilaipraphakorn N, Suratako S, Sarasamkan J, Wongsa P, et al. Diagnosis in hepatocellular carcinoma using 11C-Choline PET/CT by comparison with 18F-FDG: Pilot study. Eur J Nucl Med Mol Imaging. 2011;38(Suppl 2):S373

27.

Wong LL, Okimoto G, Kwee S. Pilot study of 18F-fluorocholine PET/CT of the liver in patients with hepatocellular cancer. HPB. 2011;13(Suppl 1):75

28.

Lenzo NP, Anderson J, Campbell A, Morandeau L, De Grado TR. Fluoromethylcholine PET in recurrent multifocal hepatoma. Australas Radiol. 2007;51(Suppl 4):B299–B302PubMedCrossRef

29.

Balogova S, Bumsel F, Kerrou K, Huchet V, Nataf V, Mal F, et al. Fluorocholine(18F) has a clinical usefulness in prostate cancer and in hepatocellular carcinoma sometimes in the same patient. Méd Nucl. 2010;34:378–382CrossRef

30.

Bieze M, van Gulik TM, Bennink RJ. Hepatoblastoma evaluated by 18F-Fluoromethyl choline PET/CT. Clin Nucl Med. 2013;38:e80–e82PubMedCrossRef

31.

Kolthammer JA, Corn DJ, Tenley N, Wu C, Tian H, Wang Y, et al. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011;38:1248–1256PubMedCrossRef

32.

Kuang Y, Salem N, Corn DJ, Erokwu B, Tian H, Wang F, et al. Transport and metabolism of radiolabeled choline in hepatocellular carcinoma. Mol Pharm. 2010;7(6):2077–2092PubMedCrossRefPubMedCentral

33.

Kuang Y, Salem N, Tian H, Kolthammer JA, Corn DJ, Wu C, et al. Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11C]choline: correlation with in vivo metabolic studies. J Nucl Med. 2011;52:98–106PubMedCrossRef

34.

Salem N, Kuang Y, Wang F, Maclennan GT, Lee Z. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging. 2009;53:144–156PubMed

35.

van den Esschert JW, Bieze M, Beuers UH, van Gulik TM, Bennink RJ. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. 2011;38:436–440PubMedCrossRefPubMedCentral

36.

Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285–1289PubMedCrossRef

37.

Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008;49:1245–1248PubMedCrossRef

38.

Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51:1699–1706PubMedCrossRef

39.

Wu HB, Wang QS, Li BY, Li HS, Zhou WL, Wang QY. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med. 2011;36:1092–1097.PubMedCrossRef

40.

Fartoux L, Balogova S, Nataf V, Kerrou K, Huchet V, Rosmorduc O, et al. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nucl Med Commun. 2012;33:757–765PubMedCrossRef

41.

Bieze M, Klumpen HJ, Verheij J, Beuers U, Phoa SS, van Gulik TM, et al. Diagnostic accuracy of 18F-methyl-choline PET/CT for intra- and extrahepatic hepatocellular carcinoma. Hepatology. 2014;59:996–1006PubMedCrossRef

42.

Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol. 2014;49:46–56PubMedCrossRefPubMedCentral

43.

Bohm B, Voth M, Geoghegan J, Hellfritzsch H, Petrovich A, Scheele J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol. 2004;130:266–272PubMedCrossRef

44.

Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21–26PubMedCrossRef

45.

Pant V, Sen IB, Soin AS. Role of 18F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma. Nucl Med Commun. 2013;34:749–757PubMedCrossRef

46.

Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol. 2001;96:1877–1880PubMedCrossRef

47.

Kong YH, Han CJ, Lee SD, Sohn WS, Kim MJ, Ki SS, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma. Korean J Hepatol. 2004;10:279–287PubMed

48.

Li CW, Kuo YC, Chen CY, Kuo YT, Chiu YY, She FO, et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn Reson Med. 2005;53:770–776PubMedCrossRef

49.

Roivainen A, Forsback S, Gronroos T, Lehikoinen P, Kähkönen M, Sutinen E, et al. Blood metabolism of [methyl-11C]choline, implications for in vivo imaging with positron emission tomography. Eur J Nucl Med. 2000;27:25–32PubMedCrossRef

50.

Podo F. Tumor phospholipids metabolism. NMR Biomed. 1999;12:413–439PubMedCrossRef

51.

Treglia G, Sadeghi R. Meta-analyses and systematic reviews on PET and PET/CT in oncology: the state of the art. Clin Transl Imaging. 2013;1:73–75CrossRef

Titel: Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis
verfasst von: Francesco Bertagna
Mattia Bertoli
Giovanni Bosio
Giorgio Biasiotto
Ramin Sadeghi
Raffaele Giubbini
Giorgio Treglia
Publikationsdatum: 01.10.2014
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 4/2014
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-014-9566-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Hepatitis B virus genotype B and mutations in basal core promoter and pre-core/core genes associated with acute-on-chronic liver failure: a multicenter cross-sectional study in China

The burden of extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with cirrhosis

Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial

Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis

The natural history of HCV-related cirrhosis and its temporal progression across the different clinical stages